Skip to content
← Back to browse
LIVER Publication-derived

Integration of Kupffer cells into human iPSC-derived liver organoids for modeling liver dysfunction in sepsis

Source Li et al., 2024 · The University of Tokyo, Institute of Medical Science · 10.1016/j.celrep.2024.113918

👤 Yang Li, Yunzhong Nie, Xia Yang, Yang Liu, Xiaoshan Deng, Yoshihito Hayashi, Riana Plummer, Qinglin Li, Na Luo, Toshiharu Kasai, Takashi Okumura, Yu Kamishibahara, Takemasa Komoto, Takuya Ohkuma, Satoshi Okamoto, Yumiko Isobe, Kiyoshi Yamaguchi, Yoichi Furukawa, Hideki Taniguchi ⏱ 19 days 📋 6 phases 🧫 Human iPSC

Abstract

This protocol describes the generation of liver organoids containing Kupffer cells (KuLOs) by co-culturing human iPSC-derived erythro-myeloid progenitors (EMPs) with hiPSC-derived liver organoids. KuLOs recapitulate fetal liver hematopoiesis and can model sepsis-associated liver dysfunction when exposed to LPS and interferon-γ.

Cell source
Human iPSC
Application
Disease modeling

Protocol overview

21 steps across 6 phases

Generation of EMPs from hiPSCs Days 0–8
  1. 1 hiPSC seeding and colony formation
  2. 2 Mesoderm specification
  3. 3 Hematopoietic specification
  4. 4 Collection of hiPSC-EMPs
Generation of liver organoids (LOs) from hiPSCs Days 0–6
  1. 1 Preparation of hiPSC-derived cell components
  2. 2 Assembly of liver organoids in 3D microplates
  3. 3 Daily medium changes
Co-culture of EMPs with liver organoids to generate KuLOs Days 0–14
  1. 1 Assembly of EMP and LO co-culture
  2. 2 Medium change and growth factor optimization (Days 1–6)
  3. 3 Transition to M-CSF supplementation (Day 6–14)
  4. 4 Kupffer cell characterization and KuLO maturation
Modeling sepsis-associated liver dysfunction Days 14–16
  1. 1 Preparation of stimulation medium
  2. 2 Exposure of KuLOs to LPS/IFN-γ
  3. 3 Assessment of sepsis-like phenotype
Recovery of sepsis-induced KuLO dysfunction Days 16–19
  1. 1 Removal of endotoxin stimulation
  2. 2 Daily medium changes during recovery
  3. 3 Assessment of functional recovery
Drug screening: TAK-242 treatment during sepsis Days 14–19
  1. 1 Preparation of TAK-242-supplemented medium
  2. 2 Early TAK-242 treatment (concurrent with LPS/IFN-γ)
  3. 3 Assessment of TAK-242 efficacy
  4. 4 Accelerated recovery with TAK-242

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Li et al., 2024. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?
Use this protocol in your therapeutic or diagnostic pipeline.
Request Commercial Licence